Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...
A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...
News-Medical.Net on MSN
FOXJ1 gene may drive resistance to taxane chemotherapy in advanced prostate cancer
A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...
In this retrospective study, researchers sought to determine the efficacy, safety, and effectiveness of a reduced ARSI dose compared to a full dose in non-metastatic castration-resistant prostate ...
Oral TYK2 inhibitor deucravacitinib receives FDA approval for active psoriatic arthritis based on significantly improved ACR20 response rates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results